Tweet
ARMENICUM REGISTERED IN RUSSIA
YEREVAN, APRIL 7, NOYAN TAPAN. Armenicum was recently registered in
Russia as an ativiral and immunomodulatory drug. The scientific
director of the Armenicum program, Academician Emil Gabrielian told NT
correspondent that the main effects of the drug have been confirmed as
a result of over 2-year clinical trials in Russia. Armenicum was
studied at the Central Institute of Virology and Immunology of Russia,
then tested in some hospitals of Saint Petersburg. Most of the drugs
used to treat AIDS have side effects with their strong negative impact
on patients' state of health, in other cases viruses become resistant
to these drugs. According to E. Gabrielian, even if the viral load of
such patients declines, their condition does not improve and most of
them stop taking such drugs. E. Gabrielian said that in this respect
Armenicum basically differs from other antiretroviral drugs. It is a
drug of a new type, with a new mechanism of effect that enhances
resistance of the immune system and regulates the depressed
function. The drug causes a rapid effect: after one or two injections,
the patient's condition changes sharply and he/she can shortly lead an
active life. Armenicum was registered in Congo, Liberia and
Zambia. According to E. Gabrielian, the drug is currently undergoing
trials in India, Ukraine and Belarus.
YEREVAN, APRIL 7, NOYAN TAPAN. Armenicum was recently registered in
Russia as an ativiral and immunomodulatory drug. The scientific
director of the Armenicum program, Academician Emil Gabrielian told NT
correspondent that the main effects of the drug have been confirmed as
a result of over 2-year clinical trials in Russia. Armenicum was
studied at the Central Institute of Virology and Immunology of Russia,
then tested in some hospitals of Saint Petersburg. Most of the drugs
used to treat AIDS have side effects with their strong negative impact
on patients' state of health, in other cases viruses become resistant
to these drugs. According to E. Gabrielian, even if the viral load of
such patients declines, their condition does not improve and most of
them stop taking such drugs. E. Gabrielian said that in this respect
Armenicum basically differs from other antiretroviral drugs. It is a
drug of a new type, with a new mechanism of effect that enhances
resistance of the immune system and regulates the depressed
function. The drug causes a rapid effect: after one or two injections,
the patient's condition changes sharply and he/she can shortly lead an
active life. Armenicum was registered in Congo, Liberia and
Zambia. According to E. Gabrielian, the drug is currently undergoing
trials in India, Ukraine and Belarus.